ARTICLE | Company News
Alzheon, Bellus Health deal
October 28, 2013 7:00 AM UTC
Alzheon received exclusive, worldwide rights from Bellus to ALZ-801 (formerly BLU8499), which has completed a Phase I trial for Alzheimer's disease. ALZ -801, a small molecular inhibitor of beta am...